RCELAVITA Medical, Inc.
Price
-21%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: safety
Quality strong, a flag to check, growth steady, the market with it.
Charts
As reported to the SEC, without any scoring.
AVITA Medical, Inc. (RCEL) reported revenue of $22M in Q2 2026 (quarter ended Jun 30, 2026), up 18% from the same quarter a year earlier. That came with a gross margin of 82% and net loss of $7.7M. For the full year FY2025, revenue was $72M (+11% year on year) and net income −$49M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 11, 2026On August 5, 2026, the Company and Stedical Scientific, Inc. (“Stedical”) entered into a Global Amendment of their existing distribution agreement and manufacturing agreement (the “Global Amendment”)Material agreement entered · Form 8-K
- Aug 6, 2026Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven.Earnings release · press release
- Jun 8, 2026As disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on January 13, 2026, AVITA Medical, Inc. (the “Company”) previously entered into a Credit Agreement and Guaranty (the “Credit Agreement”) with Perceptive Credit Holdings V, LP as a lender and the administrative …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Devices
Ranks #42 of 51 by RyuScore